| 4.81 -0.14 (-2.83%) | 10-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.79 |
1-year : | 6.24 |
| Resists | First : | 4.96 |
Second : | 5.34 |
| Pivot price | 4.96 |
|||
| Supports | First : | 4.32 |
Second : | 3.6 |
| MAs | MA(5) : | 4.9 |
MA(20) : | 4.91  |
| MA(100) : | 4.81 |
MA(250) : | 4.99 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 33.3 |
D(3) : | 40.3 |
| RSI | RSI(14): 48.4 |
|||
| 52-week | High : | 7.75 | Low : | 3.71 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ COYA ] has closed above bottom band by 22.8%. Bollinger Bands are 44.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.04 - 5.07 | 5.07 - 5.1 |
| Low: | 4.75 - 4.78 | 4.78 - 4.81 |
| Close: | 4.76 - 4.82 | 4.82 - 4.86 |
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.
Sat, 10 Oct 2026
Coya Therapeutics Inc (COYA-Q) Stock Price and News - The Globe and Mail
Tue, 06 Oct 2026
Coya Therapeutics Completes Enrollment of 120 Patients in COYA 302 ALS Trial - The Clinical Trial Vanguard
Mon, 05 Oct 2026
Coya Therapeutics, Inc. (COYA) stock price, news, quote and history - Yahoo Finance Singapore
Mon, 05 Oct 2026
An ALS trial hits its enrollment target at Coya Therapeutics (COYA), with results expected in early Q2 2027. - Stock Titan
Mon, 05 Oct 2026
Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS - Business Wire
Tue, 22 Sep 2026
Coya Enrolls 100 Patients in Phase 2/3 ALS Trial of COYA 302 - Streetwise Reports
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 1.754e+007 (%) |
| Held by Institutions | 14.6 (%) |
| Shares Short | 1,090 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.083e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -270.3 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 890.4 % |
| Return on Equity (ttm) | -32.3 % |
| Qtrly Rev. Growth | 8.02e+006 % |
| Gross Profit (p.s.) | 84.48 |
| Sales Per Share | -104.38 |
| EBITDA (p.s.) | -1.54655e+007 |
| Qtrly Earnings Growth | -1.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 1.5 |
| Dividend | 0 |
| Forward Dividend | 1.19e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|